# A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer

Source: https://onco.cc/trials/nct01394679/  
OnCo record `nct01394679` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Cell>Point LLC, not yet recruiting.

## Summary

A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer is a phase 3, interventional study registered as NCT01394679 by Cell>Point LLC, with a registry enrolment figure of 154 participants, started 2025-05-01 and due to reach its primary completion in 2025-12. Interventions recorded: (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose); 18 F FDG followed by PET/CT imaging. Conditions listed: Lung Cancer. Primary outcome: Efficacy:Comparison of 99mTc-EcC-DG SPECT/CT images to 18F-FDG PET/CT images of primary lung cancer lesion and metastatic lesions. Lung eligibility wording from the registry: "The patient has had a non incisional biopsy demonstrating definitive evidence for lung cancer OR have clinical evidence and CT scan results consistent with a diagnosis of lung cancer". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT01394679
- Phase: 3
- Setting: A Multicenter Phase 3 Study Comparing the Diagnostic Accuracy of 99mTc EC DG SPECT/CT Versus 18F FDG PET/CT for Diagnosing and Staging Patients Who Have Clinical and Radiological (CT) Evidence Consistent With a Diagnosis of Lung Cancer
- Sponsor: Cell>Point LLC
- Enrolled: 154

## Sources

- ClinicalTrials.gov NCT01394679: https://clinicaltrials.gov/study/NCT01394679

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct01394679.json